公开(公告)号：US12121701B2

公开(公告)日：2024-10-22

申请号：US17582349

申请日：2022-01-24

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Jason O'Connor ,  Yibin Zheng ,  Ashutosh Zade

IPC: G16H20/17 ,  A61B5/00 ,  A61B5/145 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/142 ,  A61M5/172 ,  G16H40/67

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61B5/4866 ,  A61B5/7282 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61M5/1408 ,  A61M5/14248 ,  G16H20/17 ,  G16H40/67 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2230/201

Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

公开(公告)号：US12097355B2

公开(公告)日：2024-09-24

申请号：US18390338

申请日：2023-12-20

Applicant: INSULET CORPORATION

Inventor： Rangarajan Narayanaswami ,  Yibin Zheng ,  Mert Sevil ,  William Whiteley ,  Saeed Salavati ,  Sam Carl

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2230/201

Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.

公开(公告)号：US11935637B2

公开(公告)日：2024-03-19

申请号：US16586499

申请日：2019-09-27

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Trang Ly ,  Eric Benjamin

IPC: G16H20/17 ,  A61M5/172 ,  G16H40/67

CPC classification number: G16H20/17 ,  A61M5/1723 ,  G16H40/67 ,  A61M2205/18 ,  A61M2205/3584 ,  A61M2205/505 ,  A61M2230/201

Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

公开(公告)号：US11607493B2

公开(公告)日：2023-03-21

申请号：US16840483

申请日：2020-04-06

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Mengdi Li ,  Jason O'Connor ,  Yibin Zheng

IPC: G08B1/08 ,  A61M5/172 ,  G16H20/17 ,  G16H40/67 ,  G16H50/50 ,  G16H10/40 ,  G16H10/60 ,  G16H50/30 ,  G16H50/70 ,  G16H50/20 ,  H04L67/141

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US11324889B2

公开(公告)日：2022-05-10

申请号：US16791648

申请日：2020-02-14

Applicant: Insulet Corporation

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor

IPC: A61M5/172 ,  G06F17/17

Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

公开(公告)号：US20220062552A1

公开(公告)日：2022-03-03

申请号：US17446084

申请日：2021-08-26

Applicant: Insulet Corporation

Inventor： Ashutosh Zade ,  Jay Jantz ,  Yibin Zheng ,  Trang Ly ,  Joon Bok Lee ,  Jason O'connor ,  Ian Mclaughlin ,  Nicholas Conte ,  Steven Cardinali

IPC: A61M5/172 ,  G16H20/17

Abstract: Exemplary embodiments may perform data analytics on data regarding a user of a medicament delivery device and data regarding other users of like medicament delivery devices to provide insights and guide management of the medicament delivery device for the user. The data analytics may be so called “big data” analytics that are performed on large data sets. The data analytics may be performed on various types of data to help determine what actions, if any, the remote management should take. The data analytics may be performed by the software on the remote management device or by other computational resources, such as by other servers or cloud computing resources. Exemplary embodiments may provide for remote management of a medicament delivery device. The management may be remote in that the management is performed via a remote management device, such as a computing device, that is remotely located from the medicament delivery device.

公开(公告)号：US12257420B2

公开(公告)日：2025-03-25

申请号：US18436410

申请日：2024-02-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Mengdi Li ,  Jason O'Connor ,  Yibin Zheng

IPC: G08B1/08 ,  A61M5/172 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  H04L67/141

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US11957875B2

公开(公告)日：2024-04-16

申请号：US17112314

申请日：2020-12-04

Applicant: INSULET CORPORATION

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Steven Cardinali ,  Jason O'Connor ,  Eric Benjamin ,  Ian McLaughlin ,  David Nazzaro ,  Ashutosh Zade

IPC: A61M5/172 ,  A61M5/142 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70

CPC classification number: A61M5/1723 ,  A61M5/14248 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US11883632B2

公开(公告)日：2024-01-30

申请号：US18159353

申请日：2023-01-25

Applicant: INSULET CORPORATION

Inventor： Jason O'Connor ,  Joon Bok Lee ,  Trang Ly ,  Yibin Zheng ,  Thomas Arnold Peyser ,  Jennifer Lena Schneider

IPC: G08B21/04 ,  A61M5/172 ,  A61B5/145 ,  A61M5/142 ,  A61M5/145 ,  A61B5/00

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61M5/145 ,  A61M5/14244 ,  A61B5/486 ,  A61B5/6832 ,  A61M2005/14208 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US11801344B2

公开(公告)日：2023-10-31

申请号：US16570125

申请日：2019-09-13

Applicant: Insulet Corporation

Inventor： Steven Cardinali ,  Joon Bok Lee ,  Jason O'Connor ,  Yibin Zheng

IPC: A61M5/172 ,  G16H20/17 ,  G16H10/60 ,  A61B5/145 ,  G16H15/00 ,  A61B5/00 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  G16H10/60 ,  G16H20/17 ,  A61B5/4839 ,  A61B5/683 ,  A61M5/14244 ,  A61M2005/14208 ,  A61M2005/1726 ,  A61M2205/52 ,  A61M2230/201 ,  G16H15/00

Abstract: Disclosed are a system, methods and computer-readable medium products that provide bolus dosage calculations by a control algorithm-based drug delivery system that provides automatic delivery of a drug, such as insulin or the like, based on sensor input. Blood glucose measurement values may be received at regular time intervals from a sensor. Using the blood glucose measurements, the control algorithm may perform various calculations and determinations to provide an appropriate bolus dosage. The appropriate bolus dosage may be used to respond to a trend in a trajectory of blood glucose measurements. In addition, a bolus dosage may also be determined by the disclosed device, system, method and/or computer-readable medium product in response to an indication that a user consumed a meal.